India Deregulates Academic Clinical Trials

India has issued draft rules doing away with the need for regulatory permission for conducting clinical trials intended for academic purposes, subject to certain conditions.

India has issued draft rules doing away with the need for regulatory permission for conducting clinical trials intended for academic purposes, subject to certain conditions.

More from Anticancer

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 

A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.

Merck Gets Closer To Extending Keytruda Franchise With Subcutaneous Version

 

Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.

Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage

 

J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.

Stock Buyback Is Vote Of Confidence From Genmab Board

 
• By 

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

More from Therapy Areas

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By 

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 

A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By 

The UK giant is forecasting peak sales of $5bn plus